DENTSPLY SIRONA Inc.

WBAG:XRAY Stock Report

Market Cap: €3.6b

DENTSPLY SIRONA Valuation

Is XRAY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of XRAY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: XRAY (€18.01) is trading below our estimate of fair value (€28.56)

Significantly Below Fair Value: XRAY is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XRAY?

Key metric: As XRAY is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for XRAY. This is calculated by dividing XRAY's market cap by their current revenue.
What is XRAY's PS Ratio?
PS Ratio1x
SalesUS$3.90b
Market CapUS$3.76b

Price to Sales Ratio vs Peers

How does XRAY's PS Ratio compare to its peers?

The above table shows the PS ratio for XRAY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.3x
300888 Winner Medical
3x16.6%CN¥24.7b
603658 Autobio Diagnostics
5.4x15.8%CN¥25.4b
ANN Ansell
1.9x6.7%AU$4.9b
HAE Haemonetics
2.8x5.9%US$3.9b
XRAY DENTSPLY SIRONA
1x1.0%€3.8b

Price-To-Sales vs Peers: XRAY is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (3.3x).

Price to Sales Ratio vs Industry

How does XRAY's PS Ratio compare vs other companies in the European Medical Equipment Industry?

40 CompaniesPrice / SalesEstimated GrowthMarket Cap
XRAY 1.0xIndustry Avg. 3.6xNo. of Companies40PS03.67.210.814.418+
40 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: XRAY is good value based on its Price-To-Sales Ratio (1x) compared to the European Medical Equipment industry average (3.5x).

Price to Sales Ratio vs Fair Ratio

What is XRAY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XRAY PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate XRAY's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst XRAY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€18.01
€22.16
+23.1%
11.8%€28.95€19.30n/a14
Dec ’25€18.60
€22.71
+22.1%
18.4%€32.66€17.73n/a13
Nov ’25€21.76
€27.93
+28.4%
10.1%€33.35€24.09n/a13
Oct ’25€23.66
€27.77
+17.4%
9.4%€32.17€24.12n/a13
Sep ’25€22.79
€27.77
+21.8%
9.4%€32.17€24.12n/a13
Aug ’25€25.02
€29.33
+17.2%
10.6%€34.75€25.02n/a13
Jul ’25€23.28
€30.96
+33.0%
11.2%€35.46€25.19n/a14
Jun ’25€25.78
€31.32
+21.5%
9.8%€35.18€25.00n/a14
May ’25€28.19
€34.17
+21.2%
10.6%€39.46€25.37n/a15
Apr ’25€30.80
€33.52
+8.8%
11.0%€38.76€24.92n/a14
Mar ’25€30.70
€33.52
+9.2%
11.0%€38.76€24.92n/a14
Feb ’25€32.04
€33.38
+4.2%
11.7%€38.69€24.87n/a13
Jan ’25€32.26
€31.04
-3.8%
11.8%€37.26€24.54n/a13
Dec ’24€29.54
€31.27
+5.9%
11.6%€37.80€24.89€18.6013
Nov ’24€28.84
€38.43
+33.2%
14.4%€48.19€26.46€21.7612
Oct ’24€32.66
€41.59
+27.3%
7.8%€47.90€36.63€23.6611
Sep ’24€34.70
€40.48
+16.7%
7.0%€46.34€36.35€22.7911
Aug ’24€37.82
€40.00
+5.8%
7.8%€46.37€36.37€25.0211
Jul ’24€36.28
€40.17
+10.7%
7.7%€46.27€36.29€23.2811
Jun ’24€34.44
€40.17
+16.6%
7.7%€46.27€36.29€25.7811
May ’24€36.98
€37.04
+0.2%
7.8%€41.02€32.82€28.1911
Apr ’24€35.94
€37.08
+3.2%
6.9%€41.90€33.52€30.8011
Mar ’24€35.18
€37.26
+5.9%
6.7%€42.21€33.76€30.7011
Feb ’24€33.83
€32.36
-4.3%
9.0%€36.80€26.68€32.0411
Jan ’24€30.12
€33.13
+10.0%
8.9%€38.46€27.89€32.2611
Dec ’23€29.37
€33.13
+12.8%
8.9%€38.46€27.89€29.5411

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 12:18
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

DENTSPLY SIRONA Inc. is covered by 38 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBaird
Jeffrey JohnsonBaird
Ishan MajumdarBaptista Research